PORTLAND, Ore., Dec. 11, 2017 -- Cromos™ Pharma, a premier regional contract research organization announced today that Stephanie Finnegan has been appointed as its Chief Operating Officer. Ms. Finnegan will join the company's US office and will oversee its European and US operations.
"We are very excited to see Ms. Finnegan joining our team," said Dr. Vlad Bogin, Cromos™ Pharma's CEO. "She brings decades of clinical research and business development experience and her addition marks a quantitative change in the company’s development. We plan to utilize Stephanie’s knowledge of US and international clinical operations to further Cromos™ Pharma's reputation of a fully integrated CRO capable of providing a full spectrum of services to biotech and pharma companies of all sizes," continued Dr. Bogin.
“Joining CromosTM Pharma was an easy decision for me,” Ms. Finnegan said. “I was looking for an opportunity to do what I enjoy most; to work with a young and growing company looking to establish a global presence. After meeting with Dr. Bogin and the leadership team at Cromos, I knew that this was the right fit. The team is talented, eager, and dedicated to unimpeachable quality and client service. There is limitless potential here and I am honored to become a member of the Cromos family.”
Ms. Finnegan has nearly three decades of experience in the biopharmaceutical industry. Prior to joining Cromos™ Pharma, she was the president of a US-based CRO that operated predominantly in Eastern Europe, and helped to lead that CRO into the global market and establish a dominant position in biologics and biosimilars. Prior to joining the CRO, Ms. Finnegan founded and led the biopharmaceutical industry’s first contract manufacturer dedicated to the clinical development of biotherapeutics. Over the past twenty-five years, she has become a recognized thought leader in global clinical development strategy and execution.
About Cromos™ Pharma
Cromos™ Pharma, LLC is a US-based contract research organization (CRO) with strong operational presence in the post-Soviet space and in Eastern/Central Europe. The company provides a full spectrum of trial-related services which include clinical monitoring, regulatory approvals, medical writing, feasibility assessments, project management and warehousing. Cromos™ Pharma, LLC is a privately owned company.
CONTACT INFORMATION
Vladimir Krechikov, MD, PhD
Director of Business Development
Tel/Fax: +353 190 36 290
Email: [email protected]
www.cromospharma.com


Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Anta Sports Expands Global Footprint With Strategic Puma Stake
Washington Post Publisher Will Lewis Steps Down After Layoffs
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 



